Valion Bio, Inc. (VBIO) Gross Margin
- Gross margin · 12 months: Value -58.09%; Formula and calculation Gross profit / revenue. Period ending 2025-09-30..
Gross margin
Overview →Financial period ending 2025-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | -58.09% | Gross profit / revenue. Period ending 2025-09-30. $-280.00K ÷ $482.00K × 100 ≈ -58.09% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | -280.00K USD | Gross Profit |
| Revenue | 482.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-09-30 | $-280.00K | $482.00K | (m) | -58.09% |
| 2025-06-30 | $-91.00K | $462.00K | (m) | -19.70% |
| 2025-03-31 | $-115.00K | $516.00K | (m) | -22.29% |
| 2024-12-31 | $2.00K | $780.00K | (m) | 0.26% |
| 2024-09-30 | $246.00K | $957.00K | (m) | 25.71% |
| 2024-06-30 | $310.00K | $1.11M | (m) | 27.85% |
| 2024-03-31 | $341.00K | $1.13M | (m) | 30.07% |
| 2023-12-31 | $287.00K | $1.18M | (m) | 24.40% |
| 2023-09-30 | $325.00K | $1.23M | (m) | 26.49% |
| 2023-06-30 | $277.00K | $1.42M | (m) | 19.49% |
| 2023-03-31 | $342.00K | $1.79M | (m) | 19.13% |
| 2022-12-31 | $299.00K | $1.84M | (m) | 16.25% |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | $10.00K | $1.36M | (m) | 0.73% |
| 2022-01-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-38.00K | $1.26M | (m) | -3.02% |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |